<DOC>
	<DOCNO>NCT01323478</DOCNO>
	<brief_summary>To evaluate long-term safety tolerability flexible dos , 15 20 mg/day , Vortioxetine period 52 week patient Major Depressive Disorder ( MDD )</brief_summary>
	<brief_title>Open-label Safety Extension Study 15 20 mg Vortioxetine ( Lu AA21004 ) Long-term Treatment Major Depressive Disorder Adults</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Patients complete 8week shortterm treatment study , 13267A ( NCT01140906 ) , Major Depressive Episode immediately prior enrolment extension study Any current psychiatric disorder MDD define Diagnostic Statistical Manual Mental Disorders , 4th edition , Text Revision ( DSMIV TR ) Female patient childbearing potential use effective contraception Use psychoactive medication The patient , investigator 's clinical judgment , significant risk suicide . Other protocoldefined inclusion exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Depressive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Depressive Disorder , Major</keyword>
	<keyword>Mood Disorders</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Behavioural Symptoms</keyword>
</DOC>